Welcome to Albumedix's bookshelf - here you will find scientific papers authored and co-authored by some of Albumedix's leading scientists as well as our collaborators and partners.

# Title
1 Q&A: Albumin in cell culture
2 Site-selective conjugation of an anticoagulant aptamer to recombinant albumins and maintenance of neonatal Fc receptor binding
3 Stoichiometric and irreversible cysteine-selective protein modification using carbonylacrylic reagents
4 Excipient Selection for Protein Stabilization
5 Tunable Half-Life Technology
6 The Research Race to Make Drugs More Efficient. Darrell Sleep. WSJ May 2014
7 The Emergence of Antibody Fragments and Derivatives
8 The need for improved half-life extension technologies
9 Recombinant Human Albumin:Delivering the Future of Type 2 Diabetes Medication
10 Preparation of Tc-99m-macroaggregated albumin from recombinant human albumin for lung perfusion imaging.
11 Phase I comparability of recombinant human albumin and human serum albumin.
12 Measles, mumps, and rubella virus vaccine (M-M-R™II): a review of 32 years of clinical and postmarketing experience.
13 Data set for mass spectrometric analysis of recombinant human serum albumin from various expression systems
14 Determination of supplier-to-supplier and lot-to-lot variability in glycation of recombinant human serum albumin expressed in Oryza sativa.
15 Serial coupling of ion-exchange and size-exclusion chromatography to determine aggregation levels in mAbs in the presence of a proteinaceous excipient, recombinant human serum albumin
16 The production, characterisation and enhanced pharmacokinetics of scFv–albumin fusions expressed in Saccharomyces cerevisiae
17 Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding.
18 Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor
19 Single-chain Variable Fragment Albumin Fusions Bind the Neonatal Fc Receptor (FcRn) in a Species-dependent Manner: IMPLICATIONS FOR IN VIVO HALF-LIFE EVALUATION OF ALBUMIN FUSION THERAPEUTICS
20 Albumin as a versatile platform for drug half-life extension.
21 Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding.
22 Dissection of the Neonatal Fc Receptor (FcRn)-Albumin Interface Using Mutagenesis and Anti-FcRn Albumin-blocking Antibodies.
23 Interaction with Both Domain I and III of Albumin Is Required for Optimal pH-dependent Binding to the Neonatal Fc Receptor (FcRn)
24 Albumin and its application in drug delivery
25 A platform for efficient, thiol-stable conjugation to albumin’s native single accessible cysteine
26 Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
27 Neonatal Fc Receptor Binding Tolerance toward the Covalent Conjugation of Payloads to Cysteine 34 of Human Albumin Variants.
28 Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs. (1)
29 Bio-reduction of Redox-Sensitive Albumin Conjugates in FcRn-Expressing Cells† (1)
30 Bio-reduction of Redox-Sensitive Albumin Conjugates in FcRn-Expressing Cells†

Send now